Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ra Pharmaceuticals Inc (NQ: RARX )

47.99 USD UNCHANGED
Last Price Updated: 7:32 PM EDT, Apr 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ra Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 8,387,097 shares of its common stock, at a public offering price of $15.50 per... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced positive top-line results from the Company’s Phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis... 
From Business Wire News Releases
Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada. The... 
From Business Wire News Releases
Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically important... 
From Business Wire News Releases
ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Add after last paragraph of release: two financial tables. 
From Business Wire News Releases
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that senior management will present at the following upcoming investor conferences: 
From Business Wire News Releases
Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced positive results from the Company’s Phase 1b pharmacokinetic (PK) study evaluating zilucoplan (RA101495 SC) in patients with renal impairment. The... 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma, will present at the 2018 Cantor Global Healthcare Conference on Tuesday,... 
From Business Wire News Releases
Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Aoife M. Brennan, M.B., B.Ch., to its board of directors. 
From Business Wire News Releases
Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its global Phase 3 program of RA101495 SC for... 
From Business Wire News Releases
Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RA PHARMCTL INC... 
From GlobeNewswire News Releases
Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the second quarter ended June 30, 2018 and highlighted recent progress in advancing its pipeline programs, including... 
From Business Wire News Releases
Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation of scientific data at the 23rd Congress of the European Hematology Association (EHA), June 14-17, 2018 in Stockholm, Sweden. 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC for the treatment of generalized myasthenia gravis (gMG) will be presented at the 4th... 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Research Report Identifies Brady, RA PHARMCTL INC, Sigma Designs, Teva Pharmaceutical Industries, Bridge, and BOK Financial with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation... 
From GlobeNewswire News Releases
Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from the Company’s oral, small molecule, complement C5 inhibitor program and data from the Company’s global, Phase 2 clinical program... 
From Business Wire News Releases
Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate and clinical developments. 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC as a treatment for generalized myasthenia gravis (gMG) will be presented in an oral... 
From Business Wire News Releases
Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Recent Analysis Shows Jack Henry & Associates, Omnicell, Surgery Partners, Floor & Decor, NVE, and RA PHARMCTL INC Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jack Henry & Associates,... 
From GlobeNewswire News Releases
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focused on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (NASDAQ: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 8,400,000 shares of its common stock at a public offering price of $6.00 per... 
From Business Wire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.